Eisai, GE reach R&D deal for Alzheimer's

04/28/2013 | DOTMed.com · AuntMinnie.com (free registration)

GE Healthcare has announced a collaboration with Eisai focused on research and development of treatments for Alzheimer's disease. GE said its candidate PET agent flutemetamol will be used by Eisai in choosing patients for an early-stage study of Eisai's beta-site amyloid precursor protein-cleaving enzyme inhibitor E2609 as a possible treatment for the disease.

View Full Article in:

DOTMed.com · AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA